Medscape weighs GLP-1 medications against finerenone to see which does more to protect the kidneys.
Recap by typeshit. Full story at Medscape.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A law firm backed explainer that notes 4,025 cases pending in MDL 3094 as of October 2026, with no trials or settlements yet, alongside a case review pitch.
The platform will become a subscription feature in the Health Lives Here app, with revenue shared between the companies. It's a company press release.
Loading…